Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 2 Similar Profiles
Pancreatic Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Adenocarcinoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Survival Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Radiotherapy Medicine & Life Sciences
Pancreas Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2018

Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers

Schunke, K. J., Rosati, L. M., Zahurak, M., Herman, J. M., Narang, A. K., Usach, I., Klein, A. P., Yeo, C. J., Korman, L. T., Hruban, R. H., Cameron, J. L., Laheru, D. A. & Abrams, R. A. Jan 1 2018 (Accepted/In press) In : Advances in Radiation Oncology.

Research output: Research - peer-reviewArticle

Mitomycin
Pancreatic Neoplasms
Prospective Studies
Survival
Fluorouracil

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Bendell, J. C., Javle, M., Bekaii-Saab, T. S., Finn, R. S., Wainberg, Z. A., Laheru, D. A., Weekes, C. D., Tan, B. R., Khan, G. N., Zalupski, M. M., Infante, J. R., Jones, S., Papadopoulos, K. P., Tolcher, A. W., Chavira, R. E., Christy-Bittel, J. L., Barrett, E. & Patnaik, A. Feb 28 2017 In : British Journal of Cancer. 116, 5, p. 575-583 9 p.

Research output: Research - peer-reviewArticle

MEK162
Maximum Tolerated Dose
Biliary Tract Neoplasms
Neoplasms
Pharmacokinetics

BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer

Pishvaian, M. J., Biankin, A. V., Bailey, P., Chang, D. K., Laheru, D., Wolfgang, C. L. & Brody, J. R. Apr 11 2017 In : British Journal of Cancer. 116, 8, p. 1021-1026 6 p.

Research output: Research - peer-reviewArticle

Platinum
Pancreatic Neoplasms
Mutation
Therapeutics
Poly(ADP-ribose) Polymerase Inhibitors
Neuroendocrine Tumors
Names
Immunohistochemistry
Recurrence

Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer

Shrestha, B. , Sun, Y. , Faisal, F. , Kim, V. , Soares, K. , Blair, A. , Herman, J. M. , Narang, A. , Dholakia, A. S. , Rosati, L. , Hacker-Prietz, A. , Chen, L. , Laheru, D. A. , De Jesus-Acosta, A. , Le, D. T. , Donehower, R. , Azad, N. , Diaz, L. A. , Murphy, A. , Lee, V. & 11 others Fishman, E. K., Hruban, R. H., Liang, T., Cameron, J. L., Makary, M., Weiss, M. J., Ahuja, N., He, J., Wolfgang, C. L., Huang, C. Y. & Zheng, L. Jul 1 2017 In : Cancer Medicine. 6, 7, p. 1552-1562 11 p.

Research output: Research - peer-reviewArticle

Pancreatic Neoplasms
Drug Therapy
Survival
Neoadjuvant Therapy
Adenocarcinoma